Cell Therapy Market by Cell Type (Differentiated Cell, Stem Cell), Therapy Type (Allogenic Therapies, Autologous Therapies), Application, End-User - Global Forecast 2024-2030
The Cell Therapy Market size was estimated at USD 8.66 billion in 2023 and expected to reach USD 9.60 billion in 2024, at a CAGR 10.93% to reach USD 17.91 billion by 2030.
The cell therapy market encompasses the research, development, manufacturing, and commercialization of products and techniques aimed at treating, mitigating, or preventing diseases by administering living cells. The escalating demand for regenerative medicine and advancements in cellular therapeutics primarily drives the growth of the cell therapy market. The rising investment in research and development and collaborative efforts between pharmaceutical companies and research institutions have accelerated the pipeline for cell therapy products. Furthermore, supportive regulatory frameworks and the designation of fast-track approvals for groundbreaking therapies have been crucial growth stimulants for the market. However, the cell therapy market faces several limitations, such as the high cost of therapies, intricate manufacturing processes, and stringent regulatory requirements, which may slow down market entry. Issues related to the preservation, transport, and shelf-life of cell therapies also present substantial challenges in the market growth. Moreover, breakthroughs in gene editing technologies such as CRISPR/Cas9 have opened new avenues for targeted cell therapies, which could offer precision medicine solutions for previously untreatable conditions. The increasing adoption of 3D bioprinting and artificial intelligence for optimizing cell therapy production holds significant promise for future market expansion.
Regional Insights
In the Americas region, the United States and Canada lead in cell therapy advancements, driven by significant research, heavy investment, and active participation from biotechnological and pharmaceutical giants. The regulatory framework in the region allows for an expedited review of novel cell therapies, hastening up the process of bringing new treatments to market. The European countries exhibit a cooperative approach towards cell therapy research, with various cross-country partnerships and funding programs supported by public and private sectors. Customer behavior in the EU is influenced by a strong predisposition towards state-funded healthcare systems, which affects access to and affordability of cell therapies. The Middle East and Africa (MEA) present a diverse picture, with countries such as Israel, UAE, and Saudi Arabia taking strides in cell therapy, while many African nations are still developing capabilities in this area. In the APAC region, the governments in China, India, and Japan have initiated several investments and reforms to fast-track local cell therapy research and commercialization. The rising prevalence of cancers and genetic diseases in the region is significantly increasing the need for cell-based therapies for disease management.
Market Insights
Market Dynamics
The market dynamics represent an ever-changing landscape of the Cell Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
Improvements in Cell Therapy Supply Chain
Market Restraints
Side Effects Related to the Stem Cell Transplant
Market Opportunities
Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
Increasing Use of Stem Cells for the Treatment of Neurological disorders
Market Challenges
Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues
Market Segmentation Analysis
Cell Type: Advancements in stem cells for therapeutic applications
Therapy Type: Increasing adoption of autologous cell therapies for personalized medicines
Application: Advancements in dermatological applications of cell therapies
End-User: Diverse applications of cell therapies in hospitals and clinics for disease management
Market Disruption Analysis
Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cell Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cell Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Pluri Launches New Cell Therapy CDMO Division
Pluri, has expanded its operations by launching a new division, PluriCDMO, specializing in contract development and manufacturing services for the cell therapy sector. The division boasts a wealth of experience in key areas such as analytical development, process scale-up, and regulatory-approved comparability studies. Utilizing their proprietary bioreactor system for 3D cell expansion and the PluriMatrix technology, Pluri ensures high-volume, consistent, and scalable production of cell-based products.
Max Healthcare Launches CAR-T Cell Therapy to Improve Cancer Care in Delhi-NCR
Max Healthcare announced the launch of Chimeric Antigen Receptor T-cell (CAR-T) therapy, a revolutionary cancer treatment, now accessible at its Delhi-NCR facilities. This advanced therapy involves reprogramming a patient's T cells to target and eradicate cancer cells. The enablement of this treatment follows ImmunoACT's recent regulatory approval by India's Central Drugs Standard Control Organisation for its CAR-T cell product, indicating a major stride in innovative cancer care.
Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
Bayer AG has announced the inauguration of a pioneering Cell Therapy Launch Facility in Berkeley, California to expand its business operations. Designed with sustainability in mind as Bayer's first fully electric pharmaceutical manufacturing plant, this biotechnological hub underscores the company's commitment to pushing the frontiers of medicine by supporting the transition from lab to commercial scale for revolutionary treatments
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cell Therapy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., BioNTech SE, Bone Therapeutics SA, Bristol-Myers Squibb Company, Castle Creek Biosciences, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc., Lonza Group Ltd., Medipost Co., Ltd., Mesoblast Ltd., Novartis AG, NuVasive, Inc., Pfizer Inc., Sartorius AG, Smith & Nephew PLC, Stemedica Cell Technologies, Inc., Stempeutics Research Pvt. Ltd., Takeda Pharmaceutical Company Limited, TegoScience, Thermo Fisher Scientific, Inc., and Vericel Corporation.
Market Segmentation & Coverage
This research report categorizes the Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
Cell Type
Differentiated Cell
Stem Cell
Therapy Type
Allogenic Therapies
Autologous Therapies
Application
Autoimmune Diseases
Dermatology
Musculoskeletal Therapies
Oncology
End-User
Biotechnology and Pharmaceutical Companies
Hospitals and Clinics
Research Institutes
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
5.1.1.2. Improvements in Cell Therapy Supply Chain
5.1.2. Restraints
5.1.2.1. Side Effects Related to the Stem Cell Transplant
5.1.3. Opportunities
5.1.3.1. Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
5.1.3.2. Increasing Use of Stem Cells for the Treatment of Neurological disorders
5.1.4. Challenges
5.1.4.1. Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues
5.2. Market Segmentation Analysis
5.2.1. Cell Type: Advancements in stem cells for therapeutic applications
5.2.2. Therapy Type: Increasing adoption of autologous cell therapies for personalized medicines
5.2.3. Application: Advancements in dermatological applications of cell therapies
5.2.4. End-User: Diverse applications of cell therapies in hospitals and clinics for disease management
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
6. Cell Therapy Market, by Cell Type
6.1. Introduction
6.2. Differentiated Cell
6.3. Stem Cell
7. Cell Therapy Market, by Therapy Type
7.1. Introduction
7.2. Allogenic Therapies
7.3. Autologous Therapies
8. Cell Therapy Market, by Application
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Dermatology
8.4. Musculoskeletal Therapies
8.5. Oncology
9. Cell Therapy Market, by End-User
9.1. Introduction
9.2. Biotechnology and Pharmaceutical Companies
9.3. Hospitals and Clinics
9.4. Research Institutes
10. Americas Cell Therapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cell Therapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cell Therapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Pluri Launches New Cell Therapy CDMO Division
13.3.2. Max Healthcare Launches CAR-T Cell Therapy to Improve Cancer Care in Delhi-NCR
13.3.3. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale